ストックスクリーナーアプリを入手
192.86
0.05%
0.10
アフターアワーズ：
192.25
-0.61
-0.32%
前日終値:
$192.76
開ける：
$191.56
24時間の取引高:
1.87M
Relative Volume:
0.84
時価総額：
$41.34B
収益：
$742.00K
当期純損益:
$-1.37B
株価収益率:
-27.27
EPS:
-7.0731
ネットキャッシュフロー:
$-1.07B
1週間 パフォーマンス:
-5.86%
1か月 パフォーマンス:
-7.93%
6か月 パフォーマンス:
+101.36%
1年 パフォーマンス:
+334.27%
1日の値動き範囲:
$191.22
$195.28
1週間の範囲:
$188.18
$205.15
52週間の値動き範囲:
$42.18
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
650-481-6801
住所
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
192.86 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-02-27 | 再開されました | UBS | Buy |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-12 | 再開されました | Raymond James | Strong Buy |
| 2025-09-05 | 開始されました | Truist | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-08-15 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Revolution Medicines director Lorence Kim sells $3.58m in stock - investing.com
Revolution Medicines Director Lorence H. Kim Sells 14,090 Shares via Revocable Trust Under 10b5-1 Plan - Kalkine Media
Planned multimillion stock sale at Revolution Medicines (RVMD) - Stock Titan
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More. - Barron's
RVMD - Finviz
Morgan Stanley Initiates Overweight on RVMD, Highlighting RAS Pi - GuruFocus
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise - Seeking Alpha
RVMD Initiated Coverage by Morgan Stanley -- Rating Set to Overw - GuruFocus
RVMD Maintained by Stifel -- Price Target Raised to $230 - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
Revolution Medicines, Inc. (RVMD) Stock Analysis: Discovering the 19.26% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval - finance.yahoo.com
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal - finance.yahoo.com
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? - finance.yahoo.com
Revolution Medicines Got Its Breakthrough—What Moves It Next? - MarketBeat
Revolution’s Rasonque Shows Promise In Lung Cancer - insights.citeline.com
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today - Benzinga
Revolution Medicines(RVMD.US) Director Sells US$11.38 Million in Common Stock - Moomoo
RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM - GuruFocus
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - The Manila Times
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC - Quiver Quantitative
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
Revolution Medicines (RVMD) insider sale under preset trading plan - stocktitan.net
Challenging Convention to Solve the Hardest Problems in Medicine – Revolution Medicines - Oncodaily
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals - BioSpace
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines: The biotech that went all-in on RAS - Fierce Pharma
Revolution Medicines Enters Lease Agreements for New Headquarters in Redwood City - marketscreener.com
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders - webull.com
New pancreatic cancer pill priced at $480,000 per year - KTLA
Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring a Biotech Giant with 18.87% Potential Upside - DirectorsTalk Interviews
Revolution’s newly approved drug doubles pancreatic cancer survival time - Mugglehead Investment Magazine
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions - Seeking Alpha
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy - Genetic Engineering and Biotechnology News
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer - TradingView
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug - Benzinga
Revolution Medicines stock hits all-time high at 220.8 USD - Investing.com
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
Revolution Medicines Inc (RVMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mancini Anthony | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
1,774 |
353,449 |
42,116 |
| Kelsey Stephen Michael | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
5,569 |
1,109,554 |
286,307 |
| Horn Margaret A | Chief Operating Officer |
Sep 16 '26 |
Sale |
199.24 |
4,967 |
989,613 |
149,680 |
| GOLDSMITH MARK A | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
13,988 |
2,786,938 |
253,342 |
| Cislini Jeff | SVP & General Counsel |
Sep 16 '26 |
Sale |
199.24 |
3,366 |
670,631 |
52,541 |
| Anders Jack | Chief Financial Officer |
Sep 16 '26 |
Sale |
199.24 |
4,053 |
807,513 |
119,216 |
0.66%
1.97%
大文字化:
|
ボリューム (24 時間):